Diagnosis and treatment of digestive lesions remain the hold the limelight of both practitioners and scientists. Their combination worsens the prognosis in patients with chronic kidney disease in chronic glomerulonephritis, there is an imbalance of trace elements, which
More
Diagnosis and treatment of digestive lesions remain the hold the limelight of both practitioners and scientists. Their combination worsens the prognosis in patients with chronic kidney disease in chronic glomerulonephritis, there is an imbalance of trace elements, which negatively affects the course of the disease and increases the risk of such complications. The paper aims to study the effect of Minerol on the clinical manifestations of the disease in patients with combined damage to the gastroenterological zone (chronic gastroduodenitis, peptic ulcer disease) and kidneys (chronic glomerulonephritis and pyelonephritis) according to clinical, laboratory and instrumental research methods. The diagnosis was verified by esophagogastroduodenoscopy with targeted biopsy, X-ray method, ph-metry, ultrasound; association with Helicobacter pylori – according to biopsy urease and respiratory tests, the presence of urinary syndrome − generally accepted laboratory methods, and radionuclide methods, if necessary. Patients were divided into two groups aged 18-60 years. When included in the complex treatment of gastroduodenal zone and kidney lesions, the biologically active drug Minerol contributes to a faster recovery of patients and plays an indispensable role in the prevention of complications such as uremic anaemia, cardiomyopathy, etc., providing anti-inflammatory and sanogenetic effects, can be useful in the treatment of post COVID syndrome.
Manuscript profile